From a regulatory compliance perspective, Generative AI (GenAI) is already making its mark in pharma process transformation, with some impressive early pilot solutions demonstrating strong potential.
The companies expect to close the pending $16.5 billion transaction in the coming days, after securing approvals for the deal from U.S. and EU regulators.
The production facility and warehouse, slated to be completed in 2027, will be used to produce drugs for rare diseases including the inherited blood disorder hemophilia.
